{
    "organizations": [],
    "uuid": "852ac0c2e12b0e79ce219ad2f9057e364660226a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-galectin-therapeutics-proceeds-to/brief-galectin-therapeutics-proceeds-to-phase-3-development-of-gr-md-02-for-nash-cirrhosis-idUSASC0A1ZG",
    "ord_in_thread": 0,
    "title": "BRIEF-Galectin Therapeutics Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 14 (Reuters) - Galectin Therapeutics Inc:\n* GALECTIN THERAPEUTICS PROCEEDS TO PHASE 3 DEVELOPMENT OF GR-MD-02 FOR NASH CIRRHOSIS FOLLOWING FDA MEETING\n* GALECTIN THERAPEUTICS INC - TARGET POPULATION OF PHASE 3 CLINICAL TRIAL WILL BE PATIENTS WITH NASH CIRRHOSIS WITHOUT ESOPHAGEAL VARICES\n* GALECTIN THERAPEUTICS INC - “DISAGREE WITH FDA’S DECISION NOT TO GRANT BREAKTHROUGH THERAPY DESIGNATION AT THIS TIME”\n* GALECTIN THERAPEUTICS - FDA HAS NOT GRANTED BREAKTHROUGH DESIGNATION FOR PATIENTS WITH NASH CIRRHOSIS Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. 0 : 0 narrow-browser-and-phone medium-browser-and-portrait-tablet landscape-tablet medium-wide-browser wide-browser-and-larger medium-browser-and-landscape-tablet medium-wide-browser-and-larger above-phone portrait-tablet-and-above above-portrait-tablet landscape-tablet-and-above landscape-tablet-and-medium-wide-browser portrait-tablet-and-below landscape-tablet-and-below Apps Newsletters Reuters Plus Advertising Guidelines Cookies Terms of Use Privacy\nAll Quote: s delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.\n© 2018 Reuters. All Rights Reserved.",
    "published": "2018-05-14T21:17:00.000+03:00",
    "crawled": "2018-05-15T14:16:16.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "galectin",
        "therapeutic",
        "inc",
        "galectin",
        "therapeutic",
        "proceeds",
        "phase",
        "development",
        "nash",
        "cirrhosis",
        "following",
        "fda",
        "meeting",
        "galectin",
        "therapeutic",
        "inc",
        "target",
        "population",
        "phase",
        "clinical",
        "trial",
        "patient",
        "nash",
        "cirrhosis",
        "without",
        "esophageal",
        "varix",
        "galectin",
        "therapeutic",
        "inc",
        "disagree",
        "fda",
        "decision",
        "grant",
        "breakthrough",
        "therapy",
        "designation",
        "time",
        "galectin",
        "therapeutic",
        "fda",
        "granted",
        "breakthrough",
        "designation",
        "patient",
        "nash",
        "cirrhosis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle",
        "apps",
        "newsletter",
        "reuters",
        "plus",
        "advertising",
        "guideline",
        "cooky",
        "term",
        "use",
        "privacy",
        "quote",
        "delayed",
        "minimum",
        "minute",
        "see",
        "complete",
        "list",
        "exchange",
        "delay",
        "reuters",
        "right",
        "reserved"
    ]
}